Two steps forward, one step back – news on access to CDKs in second line treatment
Hello everyone,
BCNA has an update on access to CDKs as
second line treatment. Pfizer have this week advised BCNA about a new capped access
program for the CDK inhibitor palbociclib (lbrance) wh...
I am very excited! My oncologist has just phoned me to tell me that I have been given access to Palbociclib for a one off payment of $50. I was prepared to use my super to pay the $40,000.